Search Results

You are looking at 161 - 170 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury and David G. Pfister

been linked to poor prognosis among individuals with squamous cell carcinoma of the buccal mucosa. 7 In a combined analysis of 2 randomized studies of cisplatin-based chemotherapy for patients with R/M HNSCC (n = 399; ECOG 1393 and ECOG 1395), 5 factors

Full access

Modification and Implementation of NCCN Guidelines™ on Hepatobiliary Cancers in the Middle East and North Africa Region

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

molecular and targeted therapies. Sorafenib for treating hepatocellular carcinoma, for example, is too expensive to be used by most eligible patients in many countries. It is currently recommended primarily in patients with Child's A disease, precluding its

Full access

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

borderline ovarian tumors (BOTs) and low-grade epithelial ovarian carcinomas (LG-EOCs) Assess the role of surgery, chemotherapy and fertility/hormonal preservation in the management of BOTs and LG-EOCs The International Federation of Gynecology and

Full access

HSR22-150: Lymph Node Evaluation of Post-Neoadjuvant Rectal Resection Specimens in Rectal Carcinoma

Saman S Karimi and Maria Gonzalez

resection have proved to reduce the risk of recurrence of colorectal carcinoma significantly. Lymph node retrieval and assessment of rectal specimen post-neoadjuvant therapy pose a challenge to the pathologist as the quantity of lymph node retrieval are

Full access

Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience

Amy Ly, Jill C. Ono, Kevin S. Hughes, Martha B. Pitman, and Ronald Balassanian

, radial scar in an excision specimen, and papilloma. Indeterminate lesions encompassed radial scar in a core biopsy, atypical papillary lesion, flat epithelial atypia (FEA), atypical ductal hyperplasia, atypical lobular hyperplasia/lobular carcinoma in

Full access

Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma

Frederick D. Tsai and Robert I. Haddad

of salivary tumors provide some framework for management. Recent attempts to better characterize the biology of salivary gland carcinomas have been fruitful through immunohistochemical detection of targetable receptor expression. The observation

Full access

CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!

Sheel Mohanty, Priyanka Augustine, Umesh Velu, Anshul Singh, Anusha Reddy, Shirley Salins, and Krishna Sharan

INTRODUCTION - In carcinoma esophagus patients where large volumes of lymphocyte producing organs and organs with circulating lymphocytes are exposed to radiation field, Radiation induced lymphopenia (RIL) is quite profound. Absolute Lymphocyte

Full access

Radiation Therapy Advances for Treatment of Anal Cancer

Joseph M. Pepek, Christopher G. Willett, and Brian G. Czito

carcinoma. CTV delineation is particularly important given that omission of potential sites of subclinical disease may result in a so-called “marginal miss” with resultant pelvic disease recurrence. Motivated in part by this trial, the RTOG has designed

Full access

Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal

Van K. Morris and Cathy Eng

Squamous cell carcinoma of the anal canal (SCCA) is an uncommon malignancy, for which more than 8,000 new diagnoses and 1,000 deaths in the United States are expected in 2018. 1 Oncogenic subtypes of human papillomaviruses (HPV), including HPV-16

Full access

Barriers to the Use of Breast Cancer Risk Reduction Therapies

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

Breast Cancer Prevention Trial (BCPT) enrolled women based on either age of 60 years or older, or age 35 to 59 years with a modified Gail model 5-year predicted risk of breast cancer of 1.66% or greater or a history of lobular carcinoma in situ (LCIS